Vertex Pharmaceuticals Inc. closed 18.39% short of its 52-week high of $519.88, which the company reached on November 8th.

Analysis of the S&P 500 health care sector's performance, quant ratings of top companies, and expert opinions on future ...

There's robust potential in US tech, pharma and Qantas, while red flags exist in a number of ASX companies that make them ...

Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

NDAQ:VRTX) Lost Money on Vertex Pharmaceuticals Incorporated (VRTX)? You May Have Been Affected by Fraud - Contact Levi & Korsinsky ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by stock analysts at ...

Vertex Pharmaceuticals Inc. closed $108.22 short of its 52-week high ($519.88), which the company achieved on November 8th.

Vertex Pharmaceuticals VRTX has outperformed the market over the past 10 years by 1.52% on an annualized basis producing an ...

Vertex secures FDA approval for ALYFTREK and expands TRIKAFTA use, advances diabetes and kidney disease therapies, and ...

The company's collaboration partner, Vertex Pharmaceuticals(NASDAQ: VRTX), made progress activating authorized treatment centers capable of administrating Casgevy, but CRISPR still hasn't reported any ...

In a report released today, William Pickering from Bernstein maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), with ...

In a report released today, Gena Wang from Barclays maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), with a price ...